ATE259877T1 - Gegen das ca55.1 antigen gerichtete bindende strukturen - Google Patents

Gegen das ca55.1 antigen gerichtete bindende strukturen

Info

Publication number
ATE259877T1
ATE259877T1 AT95902188T AT95902188T ATE259877T1 AT E259877 T1 ATE259877 T1 AT E259877T1 AT 95902188 T AT95902188 T AT 95902188T AT 95902188 T AT95902188 T AT 95902188T AT E259877 T1 ATE259877 T1 AT E259877T1
Authority
AT
Austria
Prior art keywords
seq
antigen
directed against
binding structures
cdr2
Prior art date
Application number
AT95902188T
Other languages
English (en)
Inventor
Michael Samuel Rose
Christopher Boot
Clive Graham Copley
Douglas Stephen Paterson
Susan Margaret Hall
Andrew Firmin Wright
David Charles Blakey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939324819A external-priority patent/GB9324819D0/en
Priority claimed from GB9411089A external-priority patent/GB9411089D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE259877T1 publication Critical patent/ATE259877T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95902188T 1993-12-03 1994-11-29 Gegen das ca55.1 antigen gerichtete bindende strukturen ATE259877T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939324819A GB9324819D0 (en) 1993-12-03 1993-12-03 Proteins
GB9411089A GB9411089D0 (en) 1994-06-03 1994-06-03 Proteins
PCT/GB1994/002610 WO1995015382A1 (en) 1993-12-03 1994-11-29 Binding structures directed against the ca55.1 antigen

Publications (1)

Publication Number Publication Date
ATE259877T1 true ATE259877T1 (de) 2004-03-15

Family

ID=26303960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902188T ATE259877T1 (de) 1993-12-03 1994-11-29 Gegen das ca55.1 antigen gerichtete bindende strukturen

Country Status (14)

Country Link
US (1) US5665357A (de)
EP (1) EP0731838B1 (de)
JP (1) JP3962087B2 (de)
AT (1) ATE259877T1 (de)
AU (1) AU684863B2 (de)
CA (1) CA2174972A1 (de)
DE (1) DE69433563T2 (de)
DK (1) DK0731838T3 (de)
ES (1) ES2214494T3 (de)
GB (1) GB9424108D0 (de)
IL (1) IL111748A0 (de)
NZ (1) NZ276745A (de)
PT (1) PT731838E (de)
WO (1) WO1995015382A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
CN1414970A (zh) * 1999-09-17 2003-04-30 Gtc生物治疗学公司 以转基因方式生产的融合蛋白
WO2001019842A1 (en) * 1999-09-17 2001-03-22 Genzyme Transgenics Corporation Subunit optimized fusion proteins
US20060110771A1 (en) * 2002-03-01 2006-05-25 Masanao Katagiri Proteins capable of binding to female sex hormones and process for producing the same
JP4703566B2 (ja) * 2003-05-14 2011-06-15 イムノゲン インコーポレーティッド 薬剤複合体組成物
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
JP2009503105A (ja) * 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
ME03353B (de) 2011-03-29 2019-10-20 Immunogen Inc Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
JP2016021883A (ja) * 2014-07-17 2016-02-08 日産化学工業株式会社 ヒト大腸癌細胞Ｃｏｌｏ２０５に特異的に結合する核酸
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
RU2711930C2 (ru) 2014-11-19 2020-01-23 Иммуноджен, Инк. Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2017213858A1 (en) 2016-02-05 2018-08-16 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7357012B2 (ja) 2018-06-14 2023-10-05 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
JP7743406B2 (ja) 2019-12-16 2025-09-24 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
EP0289400A3 (de) * 1987-04-30 1990-01-24 Fairchild Weston Systems Inc. Multiplexer/Demultiplexer für asynchrone Daten mit hoher Informationsgeschwindigkeit
WO1989008114A1 (en) * 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method

Also Published As

Publication number Publication date
EP0731838A1 (de) 1996-09-18
EP0731838B1 (de) 2004-02-18
AU1113095A (en) 1995-06-19
PT731838E (pt) 2004-05-31
DE69433563T2 (de) 2004-12-23
JPH09506507A (ja) 1997-06-30
JP3962087B2 (ja) 2007-08-22
AU684863B2 (en) 1998-01-08
DK0731838T3 (da) 2004-05-24
NZ276745A (en) 1998-02-26
GB9424108D0 (en) 1995-01-18
ES2214494T3 (es) 2004-09-16
WO1995015382A1 (en) 1995-06-08
CA2174972A1 (en) 1995-06-08
US5665357A (en) 1997-09-09
IL111748A0 (en) 1995-01-24
DE69433563D1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE259877T1 (de) Gegen das ca55.1 antigen gerichtete bindende strukturen
NZ547157A (en) Interferon Alpha Antibodies and their uses
NZ593068A (en) IL-18 antibody
EA200100698A1 (ru) Моноклональные антитела человека к ctla-4
NZ614727A (en) Human antibodies that bind human tnfa
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
CA2312208A1 (en) Humanization of murine antibody
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
TW200720289A (en) Antibodies against CCR5 and uses thereof
CA2006865A1 (en) Humanized immunoglobulins and their production and use
AU638535B2 (en) Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
PT1054018E (pt) Bibliotecas de fragmentos fab e métodos para a sua utilização
WO1996020277A3 (en) Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
ECSP034714A (es) Moleculas de enlace terapeuticas
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
JPWO2020018852A5 (de)
SE9600434L (sv) Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
ATE316135T1 (de) Monoklonale antikörper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung sowie ihre verwendung
GB2297751A (en) Binding structures directed against the ca55.1 antigen
CA2538725A1 (en) Nogo-a binding molecules and pharmaceutical use thereof
NZ806561A (en) Anti-csp antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0731838

Country of ref document: EP

REN Ceased due to non-payment of the annual fee